Epstein–Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders

Nissen, Loes H C; Nagtegaal, Irıs D.; Jong, Dirk J. de; Kievit, Wietske; Derikx, Lauranne; Groenen, Patricia J.T.A.; Krieken, J. Han van; Hoentjen, Frank

doi:10.1093/ecco-jcc/jjv040

Cited by 75 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study shows that 33.3% patients have EBV infection in colonic mucosa of IBD patients, lower than that reported by other researchers (45.5-81.0%) [7][8][9][10][11]15]. It may be due to the difference in patients enrolled.…”

Section: Discussioncontrasting

confidence: 74%

“…In Spieker's study, most biopsies (UC 12/25, CD 29/31) were from colonic specimens with surgical resection [8]. According to Nissen's research, 31% of the subjects (18/58) received surgery [15]. Ciccocioppo et al [11] detected EBV in refractory and responsive patients who received immunosupprresive therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, the reduction of immunosuppression is an effective strategy to achieve morphological normalization and loss of EBV [15]. Physicians should be conscious of the increased risk of EBV infection in IBD patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease

Chen

Peng

et al. 2018

Digestion

View full text Add to dashboard Cite

Aims: This cross-sectional study is to investigate the presence of Epstein-Barr virus (EBV) in colonic mucosa of inflammatory bowel disease (IBD) patients and its correlation with the clinical disease activities and therapeutic regimens. Methods: Subjects undergoing colonoscopy for screening of polyps were recruited as control. EBV DNA load was analyzed by means of quantitative real-time polymerase chain reaction and EBV-encoded RNAs were tested by in situ hybridization in intestinal mucosa of IBD patients. EBV infection was defined as positive with either method. Clinical disease activity was assessed using the Mayo Clinic Score for ulcerative colitis and Crohn’s disease activity index for CD. Results: EBV was detectable in 33 out of 99 IBD patients (33.3%). In controls, EBV prevalence was 7.5% (3/40). We found a significant correlation between EBV prevalence and clinical disease activities (mild [10.71%, 3/28] versus moderate [32.73%, 18/55], severe [75.00%, n = 12/16], p < 0.001). However, no significant difference was found in EBV prevalence between patients who received immunosuppressive therapy and those who did not. Conclusions: EBV infection is common in colonic mucosa of IBD patients. There is a significant correlation between EBV infection and clinical disease activities of IBD. However, prospective studies are still needed to explore the exact role of EBV in IBD.

show abstract

Section: Discussioncontrasting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease

Chen

Peng

et al. 2018

Digestion

View full text Add to dashboard Cite

show abstract

“…Eine Kombinationstherapie ist nur nach genauer Nutzen-Risiko-Bewertung im Einzelfall zu erwägen, wobei eine zeitliche Begrenzung und eine genaue Überwachung wichtig sind. In einer rezenten Studie, in der ileokolonische Biopsate nach der WHO-Empfehlung für PTLD untersucht wurden, zeigte sich, dass das Auftreten monomorpher atypischer lymphoplasmazellulärer Infiltrate mit EBV-Nachweis und -Viruslast assoziiert war, wobei durch Reduktion der Immunsuppression 7/8 Patienten mukosal EBV-negativ wurden und sich die atypischen lymphoplasmazellulären Infiltrate nach 6,5 Monaten zurückbildeten [142]. In Summe ist das Lymphomrisiko vorhanden, aber gering und ein Zusammenhang mit Immunsuppression und EBV vorrangig für Purinanaloga gegeben [143,144].…”

Section: Epstein-barr-virusunclassified

“…Bezüglich der Rolle von EBV bei refraktärer Colitis (analog zu CMV) existieren erste Hinweise, dass hier ein Zusammenhang bestehen könnte [142,145]. Ob dies lediglich ein Epiphänomen oder ein kausaler Zusammenhang ist, bleibt vorerst ebenso unklar wie die Frage, ob eine antivirale Therapie auch in dieser Hinsicht sinnvoll ist, zumal EBV häufig in inflammierter gastraler und ileokolonischer Mukosa nachweisbar ist [146].…”

Section: Epstein-barr-virusunclassified

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Miehsler¹,

Dejaco

Gröchenig³

et al. 2018

Z Gastroenterol

View full text Add to dashboard Cite

Anti-TNFα-antibodies have revolutionized the therapy of inflammatory bowel diseases and other immune-mediated inflammatory diseases. Due to the increasing application of these substances, the Working Group of Inflammatory Bowel Diseases of the Austrian Association of Gastroenterology and Hepatology intended to update their consensus report on the safe use of Infliximab (published in 2010) and to enlarge its scope to cover all anti-TNFα-antibodies. The present consensus report summarizes the current evidence on the safe use of anti-TNFα-antibodies and covers the following topics: general risk of infection, bacterial infections (i. e., Clostridium difficile, Tuberculosis, food hygiene), Pneumocystis jiroveci, viral infections (i. e., Hepatitis B, Hepatitis C, HIV, CMV, VZV), vaccination in general and recommendation for vaccines, gastrointestinal aspects (i. e., perianal fistula, abdominal fistula, intestinal strictures, stenosis and bowel obstruction), dermatologic aspects (skin malignancies, eczema-like drug-related skin eruption), infusion reactions and immunogenicity, demyelinating diseases, hepatotoxicity, haematotoxicity, congestive heart failure, risk and history of malignancies, and pregnancy and breast feeding. For practical reasons, the relevant aspects are summarized in a checklist which is divided into two parts: issues to be addressed before therapy and issues to be addressed during therapy.

show abstract

Epstein‐Barr Virus‐related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti‐CD30

Montes

Trédez

Yzet

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Epstein–Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders

Cited by 75 publications

References 20 publications

The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease

The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease

Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Epstein‐Barr Virus‐related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti‐CD30

Contact Info

Product

Resources

About